Wells Fargo Initiates Coverage On Amicus Therapeutics with Overweight Rating, Announces Price Target of $18
Portfolio Pulse from Benzinga Newsdesk
Wells Fargo has initiated coverage on Amicus Therapeutics with an Overweight rating and set a price target of $18.

May 30, 2024 | 3:07 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Wells Fargo has initiated coverage on Amicus Therapeutics with an Overweight rating and set a price target of $18.
The Overweight rating and a price target of $18 from a major financial institution like Wells Fargo is likely to positively impact investor sentiment and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100